BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10360379)

  • 1. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds.
    Tentori L; Turriziani M; Franco D; Serafino A; Levati L; Roy R; Bonmassar E; Graziani G
    Leukemia; 1999 Jun; 13(6):901-9. PubMed ID: 10360379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase.
    Tentori L; Lacal PM; Benincasa E; Franco D; Faraoni I; Bonmassar E; Graziani G
    J Pharmacol Exp Ther; 1998 May; 285(2):884-93. PubMed ID: 9580640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.
    Tentori L; Portarena I; Vernole P; De Fabritiis P; Madaio R; Balduzzi A; Roy R; Bonmassar E; Graziani G
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):361-9. PubMed ID: 11345654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide.
    Tentori L; Orlando L; Lacal PM; Benincasa E; Faraoni I; Bonmassar E; D'Atri S; Graziani G
    Mol Pharmacol; 1997 Aug; 52(2):249-58. PubMed ID: 9271347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
    Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
    Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide: mechanisms of action, repair and resistance.
    Zhang J; Stevens MF; Bradshaw TD
    Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triazene compounds: mechanism of action and related DNA repair systems.
    Marchesi F; Turriziani M; Tortorelli G; Avvisati G; Torino F; De Vecchis L
    Pharmacol Res; 2007 Oct; 56(4):275-87. PubMed ID: 17897837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
    Tang JB; Svilar D; Trivedi RN; Wang XH; Goellner EM; Moore B; Hamilton RL; Banze LA; Brown AR; Sobol RW
    Neuro Oncol; 2011 May; 13(5):471-86. PubMed ID: 21377995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
    Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL
    Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
    Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
    Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells.
    Tentori L; Vernole P; Lacal PM; Madaio R; Portarena I; Levati L; Balduzzi A; Turriziani M; Dande P; Gold B; Bonmassar E; Graziani G
    Leukemia; 2000 Aug; 14(8):1451-9. PubMed ID: 10942242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.
    Tentori L; Portarena I; Bonmassar E; Graziani G
    Cell Death Differ; 2001 May; 8(5):457-69. PubMed ID: 11423906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide.
    Trivedi RN; Wang XH; Jelezcova E; Goellner EM; Tang JB; Sobol RW
    Mol Pharmacol; 2008 Aug; 74(2):505-16. PubMed ID: 18477668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
    Goellner EM; Grimme B; Brown AR; Lin YC; Wang XH; Sugrue KF; Mitchell L; Trivedi RN; Tang JB; Sobol RW
    Cancer Res; 2011 Mar; 71(6):2308-17. PubMed ID: 21406402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
    Zhang J; Stevens MF; Hummersone M; Madhusudan S; Laughton CA; Bradshaw TD
    Oncology; 2011; 80(3-4):195-207. PubMed ID: 21720182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.
    Tentori L; Graziani G; Gilberti S; Lacal PM; Bonmassar E; D'Atri S
    Leukemia; 1995 Nov; 9(11):1888-95. PubMed ID: 7475280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
    Tentori L; Portarena I; Barbarino M; Balduzzi A; Levati L; Vergati M; Biroccio A; Gold B; Lombardi ML; Graziani G
    Mol Pharmacol; 2003 Jan; 63(1):192-202. PubMed ID: 12488552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
    Cheng CL; Johnson SP; Keir ST; Quinn JA; Ali-Osman F; Szabo C; Li H; Salzman AL; Dolan ME; Modrich P; Bigner DD; Friedman HS
    Mol Cancer Ther; 2005 Sep; 4(9):1364-8. PubMed ID: 16170028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
    Wedge SR; Porteous JK; Newlands ES
    Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
    Eich M; Roos WP; Dianov GL; Digweed M; Kaina B
    Mol Pharmacol; 2010 Nov; 78(5):943-51. PubMed ID: 20729302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.